* Zealand announces new timelines for a U.S. FDA decision on
iglarlixi, the fixed-ratio combination of lixisenatide
(adlyxintm) and lantus(r), for the treatment of type 2 diabetes
The post BRIEF-Zealand Pharma announces new timelines for U.S. FDA decision on iglarlixi appeared first on NASDAQ.